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Background: VRE bacteraemia has a high mortality and continues to defy control. Antibiotic risk factors for VRE
bacteraemia have not been adequately defined. We aimed to determine the risk factors for VRE bacteraemia
focusing on duration of antibiotic exposure.
Methods: A retrospective matched nested case-control study was conducted amongst hospitalized patients at
Cambridge University Hospitals NHS Foundation Trust (CUH) from 1 January 2006 to 31 December 2012. Cases
who developed a first episode of VRE bacteraemia were matched 1:1 to controls by length of stay, year, specialty
and ward type. Independent risk factors for VRE bacteraemia were evaluated using conditional logistic
regression.
Results: Two hundred and thirty-five cases were compared with 220 controls. Duration of exposure to paren-
teral vancomycin, fluoroquinolones and meropenem was independently associated with VRE bacteraemia.
Compared with patients with no exposure to vancomycin, those who received courses of 1–3 days, 4–7 days
or.7 days had a stepwise increase in risk of VRE bacteraemia [conditional OR (cOR) 1.2 (95% CI 0.4–3.8), 3.8
(95% CI 1.2–11.7) and 6.6 (95% CI 1.9–22.8), respectively]. Other risk factors were: presence of a central venous
catheter (CVC) [cOR 8.7 (95% CI 2.6–29.5)]; neutropenia [cOR 15.5 (95% CI 4.2–57.0)]; hypoalbuminaemia
[cOR 8.5 (95% CI 2.4–29.5)]; malignancy [cOR 4.4 (95% CI 1.6–12.0)]; gastrointestinal disease [cOR 12.4 (95%
CI 4.2–36.8)]; and hepatobiliary disease [cOR 7.9 (95% CI 2.1–29.9)].
Conclusions: Longer exposure to vancomycin, fluoroquinolones or meropenem was associated with VRE bacter-
aemia. Antimicrobial stewardship interventions targeting high-risk antibiotics are required to complement infec-
tion control procedures against VRE bacteraemia.
Introduction
Over the last 20 years, VRE have emerged as a major cause of
healthcare-associated bacteraemia, disproportionally affecting im-
munocompromised and critically ill patients.1 Enterococcus faecium
has become responsible for most VRE infections following the global
dissemination of a hospital-adapted lineage.2 VRE bacteraemias
are associated with increased costs of care, length of stay and mor-
tality compared with bactaraemias caused by vancomycin-
susceptible enterococci (VSE).3,4 In contrast to other healthcare-
associated infections, rates of VRE bacteraemia have failed to de-
cline in response to a host of generic infection control interventions
in different healthcare settings5–7 and are even increasing in some
countries.8 Consequently, the identification of modifiable risk factors
for VRE bacteraemia remains a priority.
Gut carriage of VRE is a major risk factor for VRE bacteraemia.
Bloodstream infection may be preceded by high levels of VRE car-
riage in the gut.9 In recipients of allogeneic stem cell transplants,
this is observed in conjunction with loss of microbiota diversity
(particularly anaerobes), a state termed enterococcal domin-
ance.10 Exposure to a range of antibiotics increases susceptibility
to VRE intestinal colonization and progression to high-level car-
riage and bacteraemia, although the effect of individual antibiotics
varies at each step of this sequence of events.11 The rate of pro-
gression from carriage to invasive infection is also affected by
the comorbidities of the patient population.12 Length of stay,
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adherence to infection control procedures and proximity to VRE-
colonized patients or a contaminated environment are additional
modifiable factors that affect the risk of VRE colonization.13
A number of studies have identified risk factors for VRE bacter-
aemia, including haematological malignancy, renal insufficiency,
acute severity of illness, immunosuppression/neutropenia, gastro-
intestinal disease or procedures and modifiable factors such as
antibiotic exposure.14–24 Vancomycin is the antibiotic most com-
monly implicated, but not all studies agree on its role. Lastly, few
studies have quantified the effect of cumulative exposure to indi-
vidual antibiotics.15,22,23
The aim of this study was to identify modifiable risk factors for
VRE bacteraemia, in particular antibiotic exposure, using a nested
case-control study design in a centre with high rates of VRE
endemicity.
Methods
Study setting, design and participants
A retrospective matched nested case-control study was conducted
amongst hospitalized patients at Cambridge University Hospitals NHS
Foundation Trust (CUH) in the UK from 1 January 2006 to 31 December
2012. This tertiary referral teaching hospital has 1170 beds, 340 000 occu-
pied bed-days per year and a range of specialties including hepatology and
hepatobiliary surgery, solid organ transplantation (kidney, liver, pancreas
and small bowel/multivisceral), adult haematopoietic stem cell transplant-
ation, paediatric haemato-oncology, and general and neurocritical ICUs.
CUH has reported the highest number of VRE bacteraemias in England in
the national mandatory surveillance scheme from 2003 to 2012 (426/6246
or 7% of national total out of 161 hospital Trusts). An active antimicrobial
stewardship programme was in place throughout the duration of the study,
including prescribing guidelines and regular antimicrobial rounds. Infection
control practices targeting VRE did not change during the study period;
however, a line-care bundle was implemented during 2006 and a deep-
clean programme in 2007. Vancomycin and teicoplanin susceptibility was
determined by disc diffusion using BSAC breakpoints (http://www.bsac.org.
uk/wp-content/uploads/2012/02/BSAC-Susceptibility-testing-version-143.
pdf). Cases and controls were identified using the diagnostic laboratory in-
formation system and the hospital electronic database, respectively. Cases
were consecutive inpatients with their first episode of VRE bacteraemia dur-
ing the study period. Patients with presumed contaminated blood cultures
(single positive sets not necessitating the use of targeted antibiotic therapy
for symptom and bacteraemia resolution at the clinicians’ discretion) were
excluded (Table S1, available as Supplementary data at JAC Online).
Controls were matched to cases in a 1:1 ratio for the following: (i) duration
of stay (matched to cases based on time from admission to day that posi-
tive blood culture was taken); (ii) year of admission; (iii) specialty; and
(iv) ward type defined as general adult, adult ICU or paediatric ward.
Specialty and ward type were treated as time-varying variables and
matched at the day of the bacteraemia. Matching for year of admission
was chosen to minimize potential confounding that may arise owing to
changes in antimicrobial prescribing or infection control practices during
the study period. Matching for specialty and ward type was used to account
for underlying comorbidities that predispose to VRE infections and for
changes in local unit VRE prevalence. Cases could serve as controls before
becoming a case and controls could serve as controls more than once.25
Covariates
Demographic, epidemiological and clinical information were selected for in-
clusion based on a literature review of risk factors for VRE bacteraemia and
extracted from paper and electronic patient records. These included
duration of hospital stay and prior ICU stay at CUH up to the point of match-
ing, in-patient transfer from another hospital at the start of the current ad-
mission and cumulative length of stay in all wards and high-risk wards at
CUH over the year prior to current admission. High-risk wards were those
associated in the literature with increased risk of VRE colonization and inva-
sive disease (adult and paediatric haemato-oncology, solid organ trans-
plant, nephrology, hepatology and ICU).26 Mortality at 30 days was
determined from hospital records or from an online national database
(NHS Spine). Usage data for all antibacterial and antifungal agents (includ-
ing treatment and prophylactic doses) were collected for 30 days prior to
matching from paper local and referring hospital records and drug charts.
Cut-offs for duration of antimicrobial exposure were chosen at 3 days and
7 days in line with current antimicrobial stewardship recommendations in
which indication for continuing antibiotics should be reviewed at 48–72 h
and prolonged courses beyond one week are discouraged in the absence of
a clear indication.27
Clinical parameters and comorbidities recorded at the time of matching
included use of gastric acid-suppressing medication; presence of a central
venous catheter (CVC); neutropenia (neutrophil count,500%106/L); im-
munosuppression (other than neutropenia); hypoalbuminaemia (albu-
min,30 g/dL); solid organ or haematological malignancy; solid organ or
haematopoietic stem cell transplantation; liver cirrhosis; gastrointestinal
disease; and hepatobiliary disease. VRE carriage was defined as growth of
VRE from any clinical culture in the 12 months prior to matching. An
additional list of candidate variables and definitions is available as
Supplementary data.
Statistical methods
Our primary analysis examined the association between exposure to anti-
microbials and the subsequent development of VRE bacteraemia. We used
univariable and multivariable logistic regression models conditioned on the
matched variable to estimate conditional ORs (cORs) and 95% CIs for the
association between independent factors and the development of VRE bac-
teraemia. Variables were evaluated in a multivariable model if differences
between cases and controls on univariable analysis showed a P value,0.2.
The final multivariable model was built using Hosmer and Lemeshow’s pur-
poseful selection.28 Statistical analyses were performed using the Stata
12.1 software package (Stata Corp., USA).
Ethics
The study was approved by the local Research Ethics Committee (reference
13/EE/0044) and by the CUH Research and Development Department
(reference A092807) and the need for informed consent was waived.
Results
We identified 295 patients with 331 episodes of VRE bacteraemia
from 1 January 2006 to 31 December 2012 (average annual inci-
dence of 12.8/100 000 occupied bed-days) (Figure 1). These origi-
nated from a base of 218 223 patients that had 380 242 overnight
admissions from 5 November 2005 to 31 December 2012. Twelve
patients could not be assessed owing to missing paper records
and 38 were excluded as their positive blood cultures were
deemed contaminants by the treating doctors. Of the remaining
245 patients, 235 defined as cases were successfully matched to
220 controls. Eight cases also served as controls before becoming
cases and seven controls were matched to cases more than once,
resulting in 235 paired comparisons.
The demographic, clinical and microbiological characteristics of
235 cases and 220 controls are shown in Table 1. Comparison be-
tween the two groups confirmed effective matching for age,
Antibiotic risk factors in VRE bacteraemia JAC
1693
gender, speciality, ward type, year and length of stay. Thirty cases
were younger than 16 years and, of the adult patients, 55 (27%)
were located in an ICU at the onset of infection. VRE bacteraemia
occurred in cases a median of 16 days following admission to CUH.
E. faecium accounted for 91% and the VanA phenotype (resistance
to both vancomycin and teicoplanin) for 87% of bacteraemias. The
crude (all-cause) mortality at 30 days was higher in cases com-
pared with controls (34% versus 13%). Only two deaths occurred
in the paediatric population, both of which were cases.
A univariable analysis was performed to identify risk factors
associated with VRE bacteraemia (Table 2 and Table S2). This dem-
onstrated associations with the following: cumulative length of
stay on high-risk wards at CUH during the year preceding the cur-
rent admission; inpatient transfer from another hospital; gastric
acid-suppression therapy; presence of a CVC; neutropenia; solid
organ tumour; severe renal failure; gastrointestinal disease; hepa-
tobiliary disease; diabetes with end-organ damage; and
hypoalbuminaemia.
The univariable analysis also examined the association be-
tween VRE bacteraemia and antibiotic use (Table 3 and Table S2).
Both groups had high rates of overall exposure to antibiotics in the
preceding 30 days, but cases received antibiotics more often and
for longer durations. The commonest antibiotics prescribed in both
groups were intravenous vancomycin, meropenem, fluoroquino-
lones, piperacillin/tazobactam and metronidazole. We found an
association with VRE bacteraemia for cumulative antibiotic
duration over the prior 30 days and for exposure to intravenous
vancomycin, meropenem, cephalosporins, fluoroquinolones,
aminoglycosides, penicillins and antifungals. The duration of ex-
posure to intravenous vancomycin, meropenem, fluoroquinolones,
cephalosporins and antifungals was also associated with VRE
bacteraemia.
Factors that were significant in the univariable analysis were
then used in a multivariable analysis to define independent risk
factors for VRE bacteraemia (Table 4). After adjustment for comor-
bidities, when compared with patients who did not receive any
intravenous vancomycin, those exposed for 1–3 days, 4–7 days or
more than 7 days had a stepwise increase in the risk of developing
VRE bacteraemia [cOR of 1.2 (95% CI 0.4–3.8), 3.8 (95% CI
1.2–11.7) and 6.6 (95% CI 1.9–22.8), respectively]. Similar stepwise
increases in cORs were observed for fluoroquinolones and merope-
nem. Additional risk factors independently associated with an
increased risk of VRE bacteraemia were: presence of a CVC [cOR 8.7
(95% CI 2.6–29.5)]; neutropenia [cOR 15.5 (95% CI 4.2–57.0)];
hypoalbuminaemia [cOR 8.5 (95% CI 2.4–29.5)]; solid organ tu-
mour [cOR 4.4 (95% CI 1.6–12.0)]; gastrointestinal disease [cOR
12.4 (95% CI 4.2–36.8)]; and hepatobiliary disease [cOR 7.9 (95%
CI 2.1–29.9)].
Discussion
In this study, we found that receiving intravenous vancomycin,
fluoroquinolones or meropenem was each associated with VRE
bacteraemia. We also observed that the risk increased consider-
ably with longer durations of antibiotic exposure (exceeding 3 days
and 7 days) for each of these three agents and that the effect was
Data available for analysis 
Cases Controls
Antibiotic exposure n=233 n=234
Antibiotic duration n=232 n=231
Neutropenia duration
Gastrointestinal disease
380 242 overnight admissions between 5 November 2005 
and 31 December 2012
(218 223 patients) 
12 patients not assessed for eligibility: notes 
unavailable   
48 patients excluded    
1.  38 ineligible: contaminated blood cultures   
2.  10 eligible but not included: unable to match  
295 patients with VRE bacteraemia 
between 1 Jan. 2006 and 31 Dec. 2012 
283 patients assessed for eligibility 
235 cases 220 controls matched 1:1 by admission
year, specialty, ward type and length of
stay  
n=233
n=233
Figure 1. Selection of study population for nested case-control comparison of risk factors for VRE bacteraemia.
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independent of other risk factors. To our knowledge, our study is
the largest to investigate risk factors for VRE bacteraemia and the
first to have been performed in the UK, in a setting with high levels
of VRE endemicity similar to the situation in the USA. These results
not only demonstrate an association for these high-risk antibiotics,
but also provide a clinically important message, encouraging the
discontinuation of these agents within 48–72 h of initiation, when
appropriate, to minimize the risk of VRE bacteraemia.
The multivariable model identified previously reported markers
of disease severity that predispose to VRE bacteraemia (hypoalbu-
minaemia, neutropenia and gastrointestinal disease).16,18,23 It
also identified hepatobiliary disease as an independent risk factor,
which has not previously been distinguished from gastrointestinal
disease. These conditions are likely to predispose a colonized pa-
tient to invasive disease through gut or biliary translocation and
suggest that patients who develop VRE bacteraemia represent a
subgroup of patients with more significant comorbidities than
matched controls in the same wards and specialties, irrespective
of length of stay or nursing in ICU. The association between a CVC
and VRE bacteraemia has been reported previously and could rep-
resent a marker of severity of illness or a potential portal for
infection.18
The role of vancomycin in promoting VRE acquisition is contro-
versial and reported associations, or lack thereof, could be
Table 1. Demographic, clinical and microbiological characteristics of cases and controls
Characteristic
Cases: patients
with VRE
bacteraemia
(n"235)
Controls:
patients without
VRE bacteraemia
(n"220) P
Age (years), median (IQR) 56.6 (39.0–66.7) 57.8 (42.2–69.5) 0.34
Male 145 (61.7) 127 (57.7) 0.47
Year of admission
2005 2 (0.9) 2 (0.9) NA
2006 34 (14.5) 33 (15.0)
2007 42 (17.9) 39 (17.7)
2008 30 (12.8) 29 (13.2)
2009 39 (16.6) 33 (15.0)
2010 31 (13.2) 29 (13.2)
2011 25 (10.6) 25 (11.4)
2012 32 (13.6) 30 (13.6)
Ward at time of bacteraemia
adult general 150 (63.8) 141 (64.1) NA
adult ICU 55 (23.4) 53 (24.1)
paediatric 30 (12.8) 26 (11.8)
Time from admission to bacteraemia (cases) and matching (controls) (days), median (IQR)a 16 (9–31) 16 (8–31) NA
Lead specialty type at time of matchingb
adult haematology 67 (28.5) 57 (25.9) NA
adult oncology 4 (1.7) 4 (1.8)
adult medicine 66 (28.1) 65 (29.6)
adult solid organ transplant 31 (13.2) 31 (14.1)
adult surgery 37 (15.7) 37 (16.8)
paediatric haemato-oncology 30 (12.8) 26 (11.8)
Enterococcus faecalis 17 (7.2)
E. faecium 214 (91.1)
Other enterococcal speciesc 4 (1.7)
VanA 202/232 (87.1)
Death within 30 days of matching 79 (33.6) 28 (12.7) ,0.001d
NA, not applicable; these variables were used to match cases and controls.
Data are presented as number (%) unless indicated otherwise.
aThe onset of bacteraemia for 27 of 235 cases was within 2 days post-hospital admission; for 25 of 27 of these cases there was healthcare contact in
the preceding 3 months.
bLead specialties included 18 different options used for matching, grouped under six categories in this table. A full list of specialties is shown in the
Supplementary data.
cOther species were Enterococcus raffinosus (1), mixed E. faecalis and E. faecium (1), mixed E. faecium and E. raffinosus (1) and one unspeciated. Both
E. raffinosus isolates were phenotypically VanA.
dFisher’s exact test.
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explained by study design. A meta-analysis of early studies investi-
gating the role of vancomycin in hospital-acquired VRE coloniza-
tion or infection attributed strong associations to confounding by
length of stay, control group selection and publication bias.29 This
goes against human experimental evidence in which administra-
tion of glycopeptides orally led to gastrointestinal selection of
VRE.30 Two studies of VRE bacteraemia using controls without
enterococcal bacteraemia have implicated vancomycin exposure
as an independent risk factor,31,32 but two further recent studies
with adequate sample size failed to demonstrate this effect.18,23
Both of the latter studies were conducted in Australia where
vancomycin resistance was predominantly mediated by the vanB
operon.6 This contrasts with the CUH and UK epidemiology where
vancomycin resistance in VRE bacteraemia is predominantly medi-
ated by vanA.33,34
Carbapenem use has only been implicated as an independent
risk factor for VRE compared with VSE bacteraemia in one published
study.14 However, since VRE was predominantly caused by
ampicillin-resistant vancomycin-resistant E. faecium and VSE by
ampicillin-susceptible vancomycin-susceptible Enterococcus faecalis,
the effect could have been previously overestimated.14 This is
particularly the case as imipenem, which was the carbapenem used
in this study, has higher efficacy against ampicillin-susceptible enter-
ococci compared with other carbapenems. Our study supports the
independent association of carbapenem (meropenem) use with VRE
bacteraemia. Carbapenems have anaerobic activity, which could
promote VRE colonization.35 A number of investigators have re-
ported that antibiotics with anaerobic activity predispose to VRE colo-
nization,9 but definitions of this group of antibiotics have not been
applied consistently in the literature. Interestingly, piperacillin/tazo-
bactam, an antibiotic with a similar spectrum of activity to merope-
nem, including anaerobic, was not associated with VRE bacteraemia
here. This is consistent with murine experiments in which adminis-
tration of piperacillin/tazobactam was protective against the estab-
lishment of high-level VRE colonization36 and with some
observational studies in which antimicrobial stewardship interven-
tions involving replacement of cephalosporin use with piperacillin/
tazobactam resulted in reduction of VRE colonization.11 However,
this effect was not noted by other investigators.37 It is possible that
meropenem was preferentially used in sicker patients in our study or
that the lack of observed association with piperacillin/tazobactam
was owing to insufficient power. The impact of switching therapy
Table 2. Risk factors for VRE bacteraemia
Variable Cases (n"235) Controls (n"235) Crude cOR (95% CI) P
Comorbidities
solid organ tumour 60 (25.5) 42 (17.9) 1.7 (1.0–2.8) 0.03
haematological malignancy 94 (40.0) 86 (36.6) 1.6 (0.8–3.2) 0.17
neutropenia 89 (37.9) 38 (16.2) 6.7 (3.3–13.4) ,0.001
severe renal failure on admission 15 (6.4) 6 (2.6) 3.3 (1.1–10.0) 0.04
liver cirrhosis 29 (12.3) 24 (10.2) 2.0 (0.7–5.9) 0.21
gastrointestinal disease 67/233 (28.8) 25 (10.6) 4.6 (2.5–8.6) ,0.001
hepatobiliary disease 41 (17.5) 22 (9.4) 3.4 (1.5–7.4) 0.003
diabetes (with end-organ damage) 16 (6.8) 5 (2.1) 4.7 (1.3–16.2) 0.02
hypoalbuminaemia 209 (88.9) 150 (63.8) 8.4 (4.0–17.4) ,0.001
Clinical exposures
gastric-acid suppression 203 (86.4) 183 (77.9) 1.9 (1.1–3.2) 0.01
CVC 197 (83.8) 153 (65.1) 5.4 (2.8–10.6) ,0.001
immunosuppression (other than neutropenia) 146 (62.1) 143 (60.9) 1.2 (0.6–2.1) 0.65
abdominal procedures 85 (36.2) 71 (30.2) 1.6 (1.0–2.8) 0.07
Prior microbiology
VRE grown from clinical sample within 1 year prior to matching 38 (16.2) 25 (10.6) 1.6 (0.9–2.6) 0.09
Hospital exposure
cumulative length of stay at CUH within 1 year of current admission (all wards)
0 days 88 (37.4) 101 (43.0) 1.0 0.16
1–14 days 43 (18.3) 49 (20.9) 1.1 (0.6–1.8)
.14 days 104 (44.3) 85 (36.2) 1.5 (1.0–2.4)
cumulative length of stay at CUH within 1 year of current admission (high-risk wards)a
0 days 121 (51.5) 142 (60.4) 1.0 0.05
1–14 days 33 (14.0) 30 (12.8) 1.5 (0.8–2.7)
.14 days 81 (34.5) 63 (26.8) 1.8 (1.1–3.0)
ICU stay current admission 87 (37.0) 77 (32.8) 1.6 (0.9–2.9) 0.14
transfer from another hospital 65 (27.7) 44 (18.7) 1.7 (1.1–2.6) 0.02
Data are presented as number (%) of patients.
aHigh-risk wards included adult and paediatric haemato-oncology, solid organ transplant, nephrology, hepatology and ICU.
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from meropenem to piperacillin/tazobactam on the acquisition of
VRE infection merits further investigation.
Fluoroquinolone use has often been identified as a risk factor
for VRE bacteraemia on univariable analysis but not following
adjustment for other factors.14,18,21,23 In a meta-analysis of
10 studies reported by Harbarth et al.,38 fluoroquinolone use
was associated with VRE colonization or infection (pooled OR
2.33, 95% CI 1.5–3.61). In a recent prospective observational
study, Sa´nchez-Dı´az et al.39 showed that long-term prophylaxis
with levofloxacin in neutropenic haemato-oncology patients
led to intestinal overgrowth of hospital-adapted clones of
E. faecium.
Placing our findings into the context of the published literature,
longer courses of fluoroquinolones and meropenem may promote
gut colonization with hospital-adapted strains of E. faecium (VSE or
VRE depending on local epidemiology). Plausibly, in settings where
VRE is endemic, intravenous vancomycin could shift the balance of
the gut population and/or invasive isolates from VSE to VRE40 thus
increasing the risk of VRE bacteraemia in susceptible patients.
Gastrointestinal or hepatobiliary insults or presence of a CVC could
constitute portals of entry for the infection in heavily colonized pa-
tients, particularly those with neutropenia.
This study has a number of limitations. It was conducted in a
single centre with high endemicity of VRE and so the findings may
not apply to other settings, particularly those that utilize active
screening programmes for VRE. However, the infection control
practices in our hospital are typical for the UK and the study
included patients from all high-risk groups including adult and
paediatric populations. Thirty-eight patients with positive blood
cultures for VRE, considered a contaminant based on contempora-
neous clinical assessment, were excluded. These patients had a
comparable 30 day mortality to the control population (8%) and
repeat blood cultures performed in 33 patients (87%) were nega-
tive in the absence of treatment supporting their exclusion. Cases
and controls differed in the duration of prior hospitalizations both
at CUH and elsewhere and, despite adjusting for these in the
model, there could be residual confounding. We did not adjust for
the Charlson comorbidity index as this score is not applicable to
children, but analysed its individual components instead. Also, we
did not adjust for acute severity of illness using the Pitt bacter-
aemia or other scores, as we could not ascertain whether the
observed score was a cause or an effect of the bacteraemia.
We opted against using a case-case-control design which has
been advocated for studies of antibiotic resistance to enable
Table 3. Association between antimicrobial exposure and VRE bacteraemia
Cases (n"235) Controls (n"235) Crude cOR (95% CI) P
Antimicrobial
vancomycin (intravenous) 169/233 (72.5%) 123/234 (52.6%) 3.3 (2.0–5.4) ,0.001
vancomycin (oral) 10/233 (4.3%) 8/234 (3.4%) 1.3 (0.5–3.2) 0.64
cephalosporins 33/233 (14.2%) 18/234 (7.7%) 2.2 (1.1–4.2) 0.02
fluoroquinolones 144/234 (61.5%) 100/234 (42.7%) 2.5 (1.6–3.8) ,0.001
amoxicillin/clavulanic acid 36/233 (15.5%) 31/234 (13.3%) 1.2 (0.7–2.1) 0.49
piperacillin/tazobactam 74/233 (31.8%) 63/234 (26.9%) 1.4 (0.8–2.3) 0.21
meropenem 157/233 (67.4%) 109 (46.4%) 2.8 (1.8–4.3) ,0.001
metronidazole 70/234 (29.9%) 54/234 (23.1%) 1.5 (1.00–2.4) 0.07
aminoglycosides 53/233 (22.8%) 35/234 (15.0%) 2.00 (1.1–3.3) 0.02
penicillins 50/233 (21.5%) 36/234 (15.4%) 1.8 (1.0–3.0) 0.05
macrolides 31/233 (13.3%) 42 (17.9%) 0.7 (0.4–1.2) 0.16
antifungals 167/233 (71.7%) 128 (54.5%) 3.0 (1.8–5.1) ,0.001
Antimicrobial duration
vancomycin (intravenous)
none 64/233 (27.5%) 111/234 (47.4%) 1.0 ,0.001
1–3 days 28/233 (12.0%) 40/234 (17.1%) 1.5 (0.8–2.9)
4–7 days 49/233 (21.0%) 37/234 (15.8%) 3.2 (1.6–6.0)
.7 days 92/233 (39.5%) 46/234 (19.7%) 5.4 (2.9–10.0)
fluoroquinolones
none 90/232 (38.8%) 134/233 (57.5%) 1.0 ,0.001
1–3 days 32/232 (13.8%) 27/233 (11.6%) 2.0 (1.1–3.7)
4–7 days 39/232 (16.8%) 25/233 (10.7%) 2.6 (1.4–4.8)
.7 days 71/232 (30.6%) 47/233 (20.2%) 2.7 (1.6–4.7)
meropenem
none 76/233 (32.6%) 126/231 (54.6%) 1.0 ,0.001
1–3 days 27/233 (11.6%) 18/231 (7.8%) 2.6 (1.3–5.4)
4–7 days 39/233 (16.7%) 35/231 (15.2%) 2.1 (1.2–3.8)
.7 days 91/233 (39.1%) 52/231 (22.5%) 4.3 (2.4–7.7)
Only risk factors found to be statistically significant on multivariable analysis are shown.
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distinction between risk factors predisposing to infection by a par-
ticular organism as opposed to those specific to its resistance
marker.41 This decision was made because VRE bacteraemia tends
to occur later in the course of hospitalization than VSE bacter-
aemia,18,23 so accounting for markers of hospital exposure related
to length of stay would not have been possible. Consequently,
some of the findings should be interpreted as potentially predis-
posing to both VSE and VRE bacteraemia rather than just VRE as
explained above.
In conclusion, this study identified longer duration of exposure
to vancomycin, fluoroquinolones or meropenem as independent
risk factors for VRE bacteraemia. Antibiotic formulary interventions
have not been proven to be effective in reducing VRE bacteraemia
but are generally accepted as part of a response to curb resistant
pathogens, in addition to infection control interventions such as
handwashing and improved cleaning protocols.42,43 This study
suggests that targeting the use of a single antibiotic in an endemic
setting is unlikely to significantly affect rates of VRE bacteraemia.
Instead, a combination of approaches including antimicrobial
stewardship focusing on limiting the duration of high-risk antibi-
otics in addition to infection control interventions would be
required to curb the rates of VRE bacteraemia.
Acknowledgements
We thank Lois Chaparadza for assistance with data retrieval and Carol
Churcher for administrative support.
Funding
T. G. is a Wellcome Trust Research Training Fellow (grant number: 103387/
Z/13/Z) and has received support from Public Health England. B. W. is an
Academic Clinical Fellow supported by the National Institute for Health
Research. M. E. T. is a Clinician Scientist Fellow supported by the Academy
of Medical Sciences and the Health Foundation and is also supported by
the National Institute for Health Research Cambridge Biomedical Research
Centre. This work was also supported by the Health Innovation Challenge
Fund (WT098600, HICF-T5–342), a parallel funding partnership between
the Department of Health and Wellcome Trust.
Transparency declarations
None to declare.
Disclaimer
The views expressed in this publication are those of the authors and not
necessarily those of the Department of Health or Wellcome Trust.
Supplementary data
Supplementary data, including Tables S1 and S2, are available at JAC Online.
References
1 Werner G, Coque TM, Hammerum AM et al. Emergence and spread of
vancomycin resistance among enterococci in Europe. Euro Surveill 2008; 13:
pii"19046.
2 Lebreton F, van Schaik W, McGuire AM et al. Emergence of epidemic
multidrug-resistant Enterococcus faecium. mBio 2013;4: e00534-13.
3 Butler AM, Olsen MA, Merz LR et al. Attributable costs of enterococcal
bloodstream infections in a nonsurgical hospital cohort. Infect Control Hosp
Epidemiol 2010;31: 28–35.
4 Prematunge C, MacDougall C, Johnstone J et al. VRE and VSE bacteremia
outcomes in the era of effective VRE therapy: a systematic review and meta-
analysis. Infect Control Hosp Epidemiol 2016;37: 26–35.
5 Gouliouris T, Peacock SJ. The rise and fall of mandatory surveillance for
glycopeptide-resistant enterococcal bacteraemia in England. J Infect
2014; 68: 401–3.
6 Howden BP, Holt KE, Lam MMC et al. Genomic insights to control the emer-
gence of vancomycin-resistant enterococci. mBio 2013;4: e00412–13.
7 Sievert DM, Ricks PP, Edwards JR et al. Antimicrobial-resistant pathogens
associated with healthcare-associated infections: summary of data reported
to the National Healthcare Safety Network at the Centers for Disease Control
and Prevention, 2009–2010. Infect Control Hosp Epidemiol 2013;34: 1–14.
8 Gastmeier P, Schro¨der C, Behnke M et al. Dramatic increase in vancomycin-
resistant enterococci in Germany. J Antimicrob Chemother 2014;69: 1660–4.
9 Donskey CJ, Chowdhry TK, Hecker MT et al. Effect of antibiotic therapy in
the density of vancomycin-resistant enterococci in the stool of colonized pa-
tients. N Engl J Med 2000;343: 1925–32.
10 Taur Y, Xavier JB, Lipuma L et al. Intestinal domination and the risk of bac-
teremia in patients undergoing allogeneic hematopoietic stem cell trans-
plantation. Clin Infect Dis 2012;55: 905–14.
11 Patel R. Clinical impact of vancomycin-resistant enterococci. J Antimicrob
Chemother 2003;51: 13iii–21.
12 Salgado CD. The risk of developing a vancomycin-resistant Enterococcus
bloodstream infection for colonized patients. Am J Infect Control 2008; 36:
S175.e5–8.
13 Bonten MJM, Slaughter S, Ambergen AW et al. The role of “colonization
pressure” in the spread of vancomycin-resistant enterococci. Arch Intern Med
1998;158: 1127–32.
Table 4. Independent risk factors associated with VRE bacteraemia
Variable Adjusted cOR (95% CI) P
Vancomycin (intravenous) duration (days)
none 1.0 0.004
1–3 1.2 (0.4–3.8)
4–7 3.8 (1.2–11.7)
.7 6.6 (1.9–22.8)
Fluoroquinolone duration (days)
none 1.0 ,0.001
1–3 1.3 (0.4–3.7)
4–7 4.5 (1.6–12.9)
.7 6.9 (2.4–20.0)
Meropenem duration (days)
none 1.0 0.03
1–3 1.8 (0.5–6.4)
4–7 2.3 (0.8–6.3)
.7 3.5 (1.3–10.0)
CVC 8.7 (2.6–29.5) 0.001
Neutropenia 15.5 (4.2–57.0) ,0.001
Hypoalbuminaemia 8.5 (2.4–29.5) 0.001
Solid organ tumour 4.4 (1.6–12.0) 0.003
Hepatobiliary disease 7.9 (2.1–29.9) 0.002
Gastrointestinal disease 12.4 (4.2–36.8) ,0.001
Gouliouris et al.
1698
14 Bhavnani SM, Drake JA, Forrest A et al. A nationwide, multicenter, case-
control study comparing risk factors, treatment, and outcome for
vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn
Microbiol Infect Dis 2000;36: 145–58.
15 Haas EJ, Zaoutis TE, Prasad P et al. Risk factors and outcomes for
vancomycin-resistant Enterococcus bloodstream infection in children. Infect
Control Hosp Epidemiol 2010;31: 1038–42.
16 Kang Y, Vicente M, Parsad S et al. Evaluation of risk factors for
vancomycin-resistant Enterococcus bacteremia among previously colonized
hematopoietic stem cell transplant patients. Transpl Infect Dis 2013; 15:
466–73.
17 Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk fac-
tors for vancomycin resistance and predictors of mortality. Infect Control
Hosp Epidemiol 1999;20: 318–23.
18 Peel T, Cheng AC, Spelman T et al. Differing risk factors for vancomycin-
resistant and vancomycin-sensitive enterococcal bacteraemia. Clin Microbiol
Infect 2012;18: 388–94.
19 Peset V, Tallo´n P, Sola C et al. Epidemiological, microbiological, clinical,
and prognostic factors of bacteremia caused by high-level vancomycin-re-
sistant Enterococcus species. Eur J Clin Microbiol Infect Dis 2000;19: 742–9.
20 Shay DK, Maloney SA, Montecalvo M et al. Epidemiology and mortality
risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis
1995;172: 993–1000.
21 Vergis EN, Hayden MK, Chow JW et al. Determinants of vancomycin re-
sistance and mortality rates in enterococcal bacteremia. Ann Intern Med
2001;135: 484–92.
22 Zaas AK, Song X, Tucker P et al. Risk factors for development of
vancomycin-resistant enterococcal bloodstream infection in patients with
cancer who are colonized with vancomycin-resistant enterococci. Clin Infect
Dis 2002;35: 1139–46.
23 Cheah AL, Peel T, Howden BP et al. Case-case-control study on factors
associated with vanB vancomycin-resistant and vancomycin-susceptible
enterococcal bacteraemia. BMC Infect Dis 2014;14: 353.
24 Montecalvo MA, Horowitz H, Gedris C et al. Outbreak of vancomycin-,
ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia
in an adult oncology unit. Antimicrob Agents Chemother 1994;38: 1363–7.
25 Essebag V, Genest J Jr, Suissa S et al. The nested case-control study in
cardiology. Am Heart J 2003;146: 581–90.
26 Cookson BD, Macrae MB, Barrett SP et al. Guidelines for the control of
glycopeptide-resistant enterococci in hospitals. J Hosp Infect 2006;62: 6–21.
27 Ashiru-Oredope D, Sharland M, Charani E et al. Improving the quality of
antibiotic prescribing in the NHS by developing a new Antimicrobial
Stewardship Programme: Start Smart—Then Focus. J Antimicrob Chemother
2012;67 Suppl 1: i51–63.
28 Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY,
USA: Wiley, 2000.
29 Carmeli Y, Samore MH, Huskins C. The association between antecedent
vancomycin treatment and hospital-acquired vancomycin-resistant entero-
cocci: a meta-analysis. Arch Intern Med 1999;159: 2461–8.
30 Van der Auwera P, Pensart N, Korten V et al. Influence of oral glycopepti-
des on the fecal flora of human volunteers: selection of highly glycopeptide-
resistant enterococci. J Infect Dis 1996;173: 1129–36.
31 Furtado GHC, Mendes RE, Pignatari ACC et al. Risk factors for vancomycin-
resistant Enterococcus faecalis bacteremia in hospitalized patients: an ana-
lysis of two case-control studies. Am J Infect Control 2006;34: 447–51.
32 Worth LJ, Thursky KA, Seymour JF et al. Vancomycin-resistant
Enterococcus faecium infection in patients with hematologic malignancy: pa-
tients with acute myeloid leukemia are at high-risk. Eur J Haematol 2007; 79:
226–33.
33 Raven KE, Reuter S, Gouliouris T et al. Genome-based characterization of
hospital-adapted Enterococcus faecalis lineages. Nat Microbiol 2016; 1:
15033.
34 Raven KE, Gouliouris T, Brodrick H et al. Complex routes of nosocomial
vancomycin-resistant Enterococcus faecium transmission revealed by gen-
ome sequencing. Clin Infect Dis 2017;64: 886–93.
35 Padiglione AA, Wolfe R, Grabsch E et al. Risk factors for new detection of
vancomycin-resistant enterococci in acute-care hospitals that employ strict
infection control procedures. Antimicrob Agents Chemother 2003;47: 2492.
36 Rice LB. The complex dynamics of antimicrobial activity in the human
gastrointestinal tract. Trans Am Clin Climatol Assoc 2013;124: 123–32.
37 Paterson DL, Muto CA, Ndirangu M et al. Acquisition of rectal colonization
by vancomycin-resistant Enterococcus among intensive care unit patients
treated with piperacillin-tazobactam versus those receiving cefepime-
containing antibiotic regimens. Antimicrob Agents Chemother 2008; 52:
465–9.
38 Harbarth S, Cosgrove S, Carmeli Y. Effects of antibiotics on nosocomial
epidemiology of vancomycin-resistant enterococci. Antimicrob Agents
Chemother 2002;46: 1619–28.
39 Sa´nchez-Dı´az AM, Cuartero C, Rodrı´guez JD et al. The rise of ampicillin-
resistant Enterococcus faecium high-risk clones as a frequent intestinal colon-
izer in oncohaematologic neutropenic patients on levofloxacin prophylaxis: a
risk for bacteraemia? Clin Microbiol Infect 2016;22: 59.e1–8.
40 Moradigaravand D, Gouliouris T, Blane B et al. Within-host evolution of
Enterococcus faecium during longitudinal carriage and transition to blood-
stream infection in immunocompromised patients. Genome Med 2017; 9:
119.
41 Kaye KS, Harris AD, Samore M et al. The case-case-control study design:
addressing the limitations of risk factor studies for antimicrobial resistance.
Infect Control Hosp Epidemiol 2005;26: 346–51.
42 De Angelis G, Cataldo MA, De Waure C et al. Infection control and preven-
tion measures to reduce the spread of vancomycin-resistant enterococci in
hospitalized patients: a systematic review and meta-analysis. J Antimicrob
Chemother 2014;69: 1185–92.
43 Anderson DJ, Chen LF, Weber DJ et al. Enhanced terminal room disinfec-
tion and acquisition and infection caused by multidrug-resistant organisms
and Clostridium difficile (the Benefits of Enhanced Terminal Room
Disinfection study): a cluster-randomised, multicentre, crossover study.
Lancet 2017;389: 805–14.
Antibiotic risk factors in VRE bacteraemia JAC
1699
